Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal
By Helena Smolak
Roche will partner with U.S. biotech company Ascidian Therapeutics to develop gene therapies through its RNA exon editing technology--a method that edits exons at the kilobase level, instead of direct DNA modification--to treat neurological diseases.
The Boston-based startup said Tuesday that it would receive $42 million from Roche as an initial payment, in addition to up to $1.8 billion in research, clinical and commercial milestone payments.
Ascidian will conduct discovery and pre-clinical activities with Roche and will provide the Swiss drugmaker its rights to RNA exon editing technology for undisclosed neurological targets, it said.
The deal is complementary to Roche's own gene editing strategy and aims to benefit its neuroscience portfolio over the next five years, Roche said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
June 18, 2024 08:54 ET (12:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now